Faculty Opinions recommendation of Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

2014 ◽  
Author(s):  
Marjan Garmyn
Keyword(s):  
Melanocytic Lesions ◽  
Melanoma Patients ◽  
Digital Dermoscopy

scholarly journals Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy

2014 ◽  
Vol 134 (5) ◽  
pp. 1351-1358 ◽  
Author(s):  
Marie Perier-Muzet ◽  
Luc Thomas ◽  
Nicolas Poulalhon ◽  
Sébastien Debarbieux ◽  
Pierre-Paul Bringuier ◽  
...  
Keyword(s):  
Melanocytic Lesions ◽  
Melanoma Patients ◽  
Digital Dermoscopy

scholarly journals Dermoscopy of difficult-to-diagnose Melanomas

2016 ◽  
Vol 8 (3) ◽  
pp. 121-127
Author(s):  
Chrysoula Papageorgiou ◽  
Demetrios Ioannides ◽  
Zoe Apalla ◽  
Efstratios Vakirlis ◽  
Elisabeth Lazaridou ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Invasive Procedure ◽  
Cutaneous Lesions ◽  
Non Invasive ◽  
Melanoma Detection ◽  
Melanocytic Lesions ◽  
Melanoma Subtypes ◽  
Digital Dermoscopy ◽  
Excision Rate

Abstract Dermoscopy is a non-invasive procedure that allows the evaluation of cutaneous lesions, and is considered to be a useful tool that improves the diagnostic accuracy of melanoma. Many dermoscopic criteria of melanoma have been established and several algorithms have been created for melanoma detection. However, the recognition of some melanomas remains challenging. Melanomas on specific body sites, melanomas in patients with multiple atypical moles, and nodular melanomas represent the most difficult-to-recognize melanoma subtypes, since they typically lack the “classic” melanoma-specific criteria. This paper provides an update on dermoscopy of difficult-to-diagnose melanomas by summarizing the newest data. Lastly, we highlight the importance of digital dermoscopy in the follow-up of melanocytic lesions for the detection of incipient melanomas while maintaining a low excision rate.

Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients

Epigenomics ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 1689-1706
Author(s):  
Maurizio Cardelli ◽  
Remco van Doorn ◽  
Lares Larcher ◽  
Michela Di Donato ◽  
Francesco Piacenza ◽  
...  
Keyword(s):  
Independent Predictor ◽  
Disease Free Survival ◽  
Endogenous Retrovirus ◽  
Human Endogenous Retrovirus ◽  
Free Survival ◽  
Melanocytic Lesions ◽  
Long Interspersed Nuclear Elements ◽  
Melanoma Patients ◽  
And Gender ◽  
Disease Free

Aim: To evaluate CpG methylation of long interspersed nuclear elements 1 (LINE-1) and human endogenous retrovirus K (HERV-K) retroelements as potential prognostic biomarkers in cutaneous melanoma. Materials & methods: Methylation of HERV-K and LINE-1 retroelements was assessed in resected melanoma tissues from 82 patients ranging in age from 14 to 88 years. In addition, nevi from eight patients were included for comparison with nonmalignant melanocytic lesions. Results: Methylation levels were lower in melanomas than in nevi. HERV-K and LINE-1 methylation were decreased in melanoma patients with clinical parameters associated with adverse prognosis, while they were independent of age and gender. Hypomethylation of HERV-K (but not LINE-1) was an independent predictor of reduced disease-free survival. Conclusion: HERV-K hypomethylation can be a potential independent biomarker of melanoma recurrence.

Sentinel lymph node negative melanoma patients: compliance with recommended clinical follow-up

2006 ◽  
Vol 16 (Supplement 1) ◽  
pp. S88-S89
Author(s):  
P. Long ◽  
M. Meyers ◽  
J. Frank ◽  
D. Ollila
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Node Negative ◽  
Melanoma Patients

Lymphoscintigraphy in clinical routine practice: Reproducibility and accuracy in melanoma patients with a long-term follow-up

2014 ◽  
Vol 40 (1) ◽  
pp. 55-60 ◽  
Author(s):  
G.C. Vitali ◽  
G. Trifirò ◽  
M. Zonta ◽  
E. Pennacchioli ◽  
L. Santoro ◽  
...  
Keyword(s):  
Routine Practice ◽  
Clinical Routine ◽  
Long Term Follow Up ◽  
Melanoma Patients

Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9576-9576
Author(s):  
Kevin Lynch ◽  
Yinin Hu ◽  
Norma Farrow ◽  
Yun Song ◽  
Max Meneveau ◽  
...  
Keyword(s):  
Lymph Node ◽  
Disease Control ◽  
Lymph Node Dissection ◽  
Patient Preference ◽  
Distant Metastases ◽  
Node Dissection ◽  
Melanoma Patients ◽  
Regional Disease ◽  
In Transit

9576 Background: While management of the nodal basin for melanoma has largely moved to observation for microscopic sentinel lymph node (SLN) metastasis, complete lymph node dissection (CLND) remains the current standard of care for melanoma patients with macroscopic, clinically detectable lymph node metastases (cLN). As CLND is associated with high surgical morbidity, we sought to study whether cLN may be safely managed by excision of only clinically abnormal nodes (precision lymph node dissection, PLND). Currently, a small subset of patients with cLN do not undergo CLND because of frailty or patient preference. We hypothesized that in these selected patients, PLND would provide acceptable regional control rates. Methods: Retrospective chart review was conducted at four academic tertiary care hospitals to identify melanoma patients who underwent PLND for cLN. cLN were defined as palpable or radiographically abnormal nodes. Recurrences were categorized as local/in-transit, same-basin lymph node, or distal lymph node/visceral. The primary outcome was isolated same-basin recurrence after PLND. Results: Twenty-one patients underwent PLND for cLN without synchronous distant metastases (characteristics of primary lesions summarized in Table). Reasons for forgoing CLND included patient preference (n=8), imaging indeterminate for distant metastases (n=2), comorbidities (n=4), loss to follow up (n=1), partial response to checkpoint blockade (n=1), or not reported (n=5). The inguinal node basin was the most common site (n=10), followed by the axillary (n=8) and cervical basins (n=3). A median of 2 nodes were resected at PLND, and 68% of resected nodes were positive for melanoma (median: 1, range: 1-3 nodes). Median follow-up was 23 months from PLND, and recurrence was observed in 28.6% of patients overall. Only 1 patient (4.8%) developed an isolated same-basin recurrence. The 3-year cumulative incidence of isolated same-basin recurrence was 5.3%, while risk of isolated local/in-transit recurrence or distant basin/visceral metastasis were 19.8% and 33.3%, respectively. Complications from PLND were reported in 1 patient (4.8%) and were limited to post-operative seroma and lymphedema. Conclusions: These pilot data suggest that PLND may offer acceptable regional disease control for cLN. Post-operative morbidity from PLND was also low, raising the possibility that PLND may provide adequate regional disease control without the morbidity associated with CLND. These data justify additional, prospective evaluation of PLND in selected patients.[Table: see text]

Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases

2021 ◽  
pp. clincanres.1046.2021
Author(s):  
Anna Maria Di Giacomo ◽  
Vanna Chiarion-Sileni ◽  
Michele Del Vecchio ◽  
Pier Francesco Ferrucci ◽  
Michele Guida ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Phase Iii ◽  
Primary Analysis ◽  
Melanoma Patients

scholarly journals The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years

2019 ◽  
Vol 27 (5) ◽  
pp. 1407-1417 ◽  
Author(s):  
Eric A. Deckers ◽  
Josette E. H. M. Hoekstra-Weebers ◽  
Samantha Damude ◽  
Anne Brecht Francken ◽  
Sylvia ter Meulen ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Well Being ◽  
Significant Group ◽  
Event Scale ◽  
Free Survival ◽  
Stage Ib ◽  
Ajcc Stage ◽  
Patient Reported ◽  
Melanoma Patients

Abstract Background This study compares well-being, recurrences, and deaths of early-stage cutaneous melanoma patients in follow-up, as recommended in the Dutch guideline, with that of patients in a stage-adjusted reduced follow-up schedule, 3 years after diagnosis, as well as costs. Methods Overall, 180 eligible pathological American Joint Committee on Cancer (AJCC) stage IB–IIC, sentinel node staged, melanoma patients (response rate = 87%, 48% male, median age 57 years), randomized into a conventional (CSG, n = 93) or experimental (ESG, n = 87) follow-up schedule group, completed patient-reported outcome measures (PROMs) at diagnosis (T1): State-Trait Anxiety Inventory–State version (STAI-S), Cancer Worry Scale (CWS), Impact of Event Scale (IES), and RAND-36 (Mental and Physical Component scales [PCS/MCS]). Three years later (T3), 110 patients (CSG, n = 56; ESG, n = 54) completed PROMs, while 42 declined (23%). Results Repeated measures analyses of variance (ANOVAs) showed a significant group effect on the IES (p = 0.001) in favor of the ESG, and on the RAND-36 PCS (p = 0.02) favoring the CSG. Mean IES and CWS scores decreased significantly over time, while those on the RAND-36 MCS and PCS increased. Effect sizes were small. Twenty-five patients developed a recurrence or second primary melanoma, of whom 13 patients died within 3 years. Cox proportional hazards models showed no differences between groups in recurrence-free survival (hazard ratio [HR] 0.71 [0.32–1.58]; p = 0.400) and disease-free survival (HR 1.24 [0.42–3.71]; p = 0.690). Costs per patient after 3 years (computed for 77.3% of patients) were 39% lower in the ESG. Conclusion These results seemingly support the notion that a stage-adjusted reduced follow-up schedule forms an appropriate, safe, and cost-effective alternative for pathological AJCC stage IB–IIC melanoma patients to the follow-up regimen as advised in the current melanoma guideline.

Sign in / Sign up

Export Citation Format

Share Document